AUTHOREA
Log in Sign Up Browse Preprints

loading page

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
  • +3
  • Leona Dold,
  • Philipp Lutz,
  • Annkristin Heine,
  • Tobias Weismüller,
  • Christian Strassburg,
  • Ulrich Spengler
Leona Dold

Corresponding Author:[email protected]

Author Profile
Philipp Lutz
University Hospital Bonn
Author Profile
Annkristin Heine
University Hospital Bonn
Author Profile
Tobias Weismüller
University Hospital Bonn
Author Profile
Christian Strassburg
University Hospital Bonn
Author Profile
Ulrich Spengler
University Hospital Bonn
Author Profile

Abstract

Patients after liver transplantation have an increased risk to develop haematologic neoplasias. Information how to treat these patients in the context of immunosuppression is sparse. Here, we report two patients with polycythemia vera (PV) and myelofibrosis (MF) on ruxolitinib after liver transplantation.

Peer review status:ACCEPTED

19 Jan 2021Submitted to Clinical Case Reports
Show details
Hide details
21 Jan 2021Submission Checks Completed
21 Jan 2021Assigned to Editor
08 May 2021Reviewer(s) Assigned
22 May 2021Review(s) Completed, Editorial Evaluation Pending
24 May 2021Editorial Decision: Revise Minor
31 Jul 20211st Revision Received
31 Jul 2021Submission Checks Completed
31 Jul 2021Assigned to Editor
31 Jul 2021Review(s) Completed, Editorial Evaluation Pending
31 Jul 2021Reviewer(s) Assigned
15 Aug 2021Editorial Decision: Accept